The effects of angiotensin-receptor blockers on mortality and morbidity in heart failure: A systematic review

International Journal of Clinical Practice

Volumn 62, Issue 9, 2008, Pages 1397-1402

  Shibata, M C ^a   Tsuyuki, R T ^a   Wiebe, N ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN; PLACEBO; RECEPTOR BLOCKING AGENT; VALSARTAN;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFECT; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; DRUG COMBINATIONS; HEART FAILURE; HOSPITALIZATION; HUMANS; MIDDLE AGED;

EID: 49349109979     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01806.x     Document Type: Review

References (23)

1. Heart and Stroke Foundation of Canada. The growing bruden of heart disease and stroke in Canada 2003. Ottawa, Canada, 2003.
2. American Heart Association. 2002 Heart and Stroke Statistical Update. Dallas: American Heart Association, 2001.
3. Ennezat PV, Berlowitz M, Sonnenblick EH, Le Jemtel TH. Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure. Curr Cardiol Rep 2000 3: 258 62.
4. Macfadyen RJ, Lee AF, Morton JJ et al. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 1999 82: 57 61.
5. Lee AF, Macfadyen RJ, Struthers AD. Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study. Eur J Heart Fail 1999 4: 401 6.
6. The RESOLVD Pilot Study Investigators. Comparison of candesartan, enalapril, and their combination in congestive heart failure, RAndomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. Circulation 1999 100: 1056 64.
7. Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997 349: 747 52.
8. Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000 355: 1582 7.
9. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001 345: 1667 75.
10. McMurray JJ, Ostergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting enzyme inhibitor: the CHARM-added trial. Lancet 2003 362: 767 71.
11. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002 360: 760.
12. Pfeffer M.A., McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003 349: 1893 906.
13. Jadad AR, Moore RA, Carrol D. Is blinding necessary? Control Clin Trials 1996 17: 1 12.
14. Schulze KF, Chalmers I, Hayes RJ et al. Empirical evidence of bias. JAMA 1995 273: 408 12.
15. Dersimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986 3: 177 88.
16. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003 327: 557 60.
17. Sharma D, Buyse M, Pitt B, Rucisnka EJ. Meta-analysis of observed mortality data from all-controlled double-blind, multiple-dose studies of losartan in heart failure. Losartan Heart Failure Mortality Meta-analysis Study Group. Am J Cardiol 2000 85: 187 92.
18. Dimopoulos K, Salukhe TV, Coats AJS et al. Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in patients with chronic heart failure already receiving an ACE inhibitor (alone or with a beta-blocker). Int J Cardiol 2004 93: 105 11.
19. Lee VC, Rhew DC, Dylan M et al. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 2004 141: 693 704.
20. Jong P, Demers C, Mckelvie RS, Liu P. Angiotensin receptor blockers in heart failure: meta-analysis of randomized controlled trials. J Am Coll Cardiol 2002 39: 463 70.
21. Yusuf S, Sleight P, Pogue JP et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000 342: 145 53.
22. Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003 362: 782 8.
23. Yusuf S. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 2002 89: 18A 26A.